ERBB2 and breast cancer: Yue et al. also found a significant association between 5α-androstan-3β,17β-diol monosulfate (2) and increased risk of HER2-positive breast cancer (odds ratio [OR] = 1.07, 95% confidence interval [CI]: 1.03–1.12, p=0.0012) [29], although the study did not apply multiple testing correction.